Payables and other current liabilities |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trade and other current payables [abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and other current liabilities | Payables and other current liabilitiesNote 17.1. Trade payables and other current liabilities Trade payables and other current liabilities break down as follows:
The decrease in Trade payables as of September 30, 2025 compared to December 31, 2024 is mainly attributable to decreased activity on ABTECT as a result of reaching major milestones in the Phase 3 clinical trials. Note 17.2. Tax and employee-related payablesTax and employee-related payables are presented below:
The increase in Social security and other payables relates to social contributions on vested AGAs that have become due.
|